Blood biochemical indexes: AST (SGOT) and ALT (SGPT) ≤2.5 × upper limit of normal value (ULN);Total bilirubin (TBIL) ≤ULN;Serum creatinine (CRE) ≤1.5 × ULN;
Coagulation function: Prothrombin time (PT), international standard ratio (INR) ≤1.5 × ULN;
Comply with the study visit plan and other program requirements.
You may not be if
Accompanied by other systemic malignant tumors;
Received any form of anti-tumor therapy, including interventional chemoembolization, ablation, radiotherapy, chemotherapy, tumor palliative resection and molecular targeted therapy;
Used any other study drugs within 5 weeks before enrollment;
Central nervous system diseases, mental diseases, unstable angina pectoris, congestive heart failure, severe arrhythmia and other serious diseases that cannot be controlled;
Uncontrolled infection, bleeding, pancreatic leakage, bile leakage, or other postoperative complications during baseline examination;Acute and chronic metabolic acidosis (including ketoacidosis and lactic acidosis) has not been corrected.
A history of allergy to study drugs or similar structured drugs;
Pregnant or lactating women;
Any conditions, including serious medical risk factors, medical conditions, and laboratory abnormalities, that may impair patient safety or the integrity of research data;
Intestinal obstruction, extensive adhesion in the peritoneal cavity, abdominal inflammation, etc.
Clareo Health | Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy
